Latest Findings from Penumbra’s STRIKE-PE Study to be Presented at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Conference

New data from the ongoing STRIKE-PE study will be presented at the 36th Annual Transcatheter Cardiovascular Therapeutics® (TCT) Conference. Recent real-world data from the STRIKE-PE Study showed that Penumbra’s computer assisted vacuum thrombectomy (CAVT™) for the treatment of pulmonary embolism (PE) improves quality of life and functional outcomes. The new analyses further build on the clinical evidence supporting the impact of CAVT technology for the treatment of PE and demonstrate significant benefits for patients.

“As we continue to evaluate the impact of CAVT on patient care, we gain a better understanding of how this advanced technology can address the complex needs of PE patients,” said James F. Benenati, M.D., FSIR, chief medical officer at Penumbra. “Our studies continue to offer us a deeper look into how this innovation improves patient outcomes and expands treatment options for higher-risk patients.”

Penumbra is also conducting STORM-PE, a first-of-its kind randomized controlled trial comparing the use of Penumbra’s Lightning Flash® CAVT technology with anticoagulation versus anticoagulation alone for the treatment of PE. The study aims to fill the evidence gap on whether intermediate-high risk PE patients need treatment beyond anticoagulation and if CAVT is superior at relieving right heart strain.

Presentation Schedule

Monday, October 28th

• 2:20 pm ET – TCT 732: Right Heart Recovery After Treatment of Pulmonary Embolism with Computer Assisted Vacuum Thrombectomy: Subgroup Analysis From the First 300 Patients in the STRIKE-PE Study (First to Podium)
  Presenter: Suhail Dohad, MD, Cedars-Sinai Medical Center, Los Angeles, CA
• 2:30 pm ET – TCT 733: Periprocedural Results of an Interim Analysis of 300 Pulmonary Embolism Patients From the STRIKE-PE Study
  Presenter: Andrew S.P. Sharp, FRCP, MBBCh, MD, University College Dublin, Dublin, Ireland
• 2:40 pm ET – TCT 734: Initial Periprocedural Experience Using Computer Assisted Vacuum Thrombectomy with Lightning Flash for the Treatment of Pulmonary Embolism: A Subgroup Analysis of the STRIKE-PE Study
  Presenter: Suhail Dohad MD, Cedars-Sinai Medical Center, Los Angeles, CA

STRIKE-PE is a prospective, international, multicenter study evaluating real-world safety, performance, and long-term quality-of-life outcomes of CAVT with Penumbra’s Indigo® Aspiration System for the treatment of PE. Learn more about the STRIKE-PE Study: https://www.penumbrainc.com/strike-pe-study/

About Penumbra

Penumbra Inc., the world’s leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Its broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn and X.

Important Safety Information

Additional information about Penumbra’s products can be located on Penumbra’s website at https://www.penumbrainc.com/products/peripheral-thrombectomy-indigo-system/. Caution: Federal (USA) law restricts these devices to sale by or on the order of a physician. Prior to use, please refer to Instructions for Use for complete product indications, contraindications, warnings, precautions, potential adverse events, and detailed instructions for use. Risk information can be found at peninc.info/risk.